2024年7月8日 · Kriya is targeting diseases that impact millions of people worldwide and represent areas of high unmet need. We target validated biological pathways with innovative gene …

2024年1月5日 · Kriya is developing KRIYA-586, a one-time, adeno-associated virus (AAV) gene therapy that drives durable expression of a monoclonal antibody that blocks IGF-1 receptors.

Kriya’s KRIYA-839, an adeno-associated virus (AAV)-based gene therapy, is a groundbreaking approach to restoring insulin production and enhancing glucose metabolism in type 1 diabetes. …

Britt Petty is Chief Manufacturing Officer at Kriya. He joined Kriya from AveXis, a Novartis company, focused on the development and commercialization of gene therapies for …

2021年7月14日 · Kriya is built on two distinct technology platforms: its computationally enabled proprietary platform for rational vector design (SIRVE™) and its innovative high-efficiency …

2022年5月16日 · Kriya’s product pipeline addresses diseases of high unmet need with therapeutic area divisions in ophthalmology, oncology, rare disease, and chronic disease, each led by …

Kriya is developing a portfolio of one-time gene therapies to address common diseases. Our current pipeline includes three main therapeutic areas: Therapeutic Area

Kriya’s adeno-associated virus (AAV) gene therapy is designed to durably express an engineered ion channel focally within the trigeminal nerve, which may provide targeted pain relief.

2023年7月26日 · With operations in Palo Alto, California and Research Triangle Park, North Carolina, Kriya has raised over $600 million in committed capital, which will be used to …

2024年1月8日 · Kriya shares the latest news on our pipeline of life-changing gene therapies to address common diseases.